Видео ютуба по тегу Olaparib

Pharmaceutical Process Innovation Pitch: Olaparib | Dr Gautam Panda | CSIR-CDRI
Pharmaceutical Process Innovation Pitch: Olaparib | Dr Gautam Panda | CSIR-CDRI
Olaparib approvazione in prima linea per il tumore prostata, dopo ovaio e seno.
Olaparib approvazione in prima linea per il tumore prostata, dopo ovaio e seno.
Lynparza 150 Mg(Olapanib) Tablet Uses in Hindi||Ovarian Brest Cancer|| कैंसर को रोक सकती है ये दवा
Lynparza 150 Mg(Olapanib) Tablet Uses in Hindi||Ovarian Brest Cancer|| कैंसर को रोक सकती है ये दवा
Olaparib after chemotherapy continues to meaningfully improveme efficacy in gBRCApv and high-ris...
Olaparib after chemotherapy continues to meaningfully improveme efficacy in gBRCApv and high-ris...
I farmaci antitumorali: Olaparib, Niraparib, Rucaparib, Talazoparib | Filodiretto
I farmaci antitumorali: Olaparib, Niraparib, Rucaparib, Talazoparib | Filodiretto
19 Medicine of the week: Olaparib
19 Medicine of the week: Olaparib
Tumore: cancro prostata, oncologo Caffo ‘olaparib con terapia ormonale riduce del 71% rischio morte’
Tumore: cancro prostata, oncologo Caffo ‘olaparib con terapia ormonale riduce del 71% rischio morte’
OlympiA Study Demonstrates the Efficacy of Olaparib in the Treatment of Early Breast Cancer
OlympiA Study Demonstrates the Efficacy of Olaparib in the Treatment of Early Breast Cancer
OlympiA Update from SABCS 2024 – Adjuvant Olaparib Use in BRCA1/BRCA2 HER2 Negative Breast Cancer
OlympiA Update from SABCS 2024 – Adjuvant Olaparib Use in BRCA1/BRCA2 HER2 Negative Breast Cancer
Olaparib: Avances en el Tratamiento de Cánceres con Mutaciones BRCA | Información Esencial
Olaparib: Avances en el Tratamiento de Cánceres con Mutaciones BRCA | Información Esencial
Study Updates for Patients with a BRCA Mutation and Prior Breast Cancer
Study Updates for Patients with a BRCA Mutation and Prior Breast Cancer
Studio OlympiA: arrivano ulteriori conferme dai dati a lungo termine su olaparib
Studio OlympiA: arrivano ulteriori conferme dai dati a lungo termine su olaparib
POLAR: pembrolizumab and olaparib in HRD-positive pancreatic cancer
POLAR: pembrolizumab and olaparib in HRD-positive pancreatic cancer
Exploring the role of olaparib and treatment intensification in breast cancer
Exploring the role of olaparib and treatment intensification in breast cancer
Exploring the role of olaparib and treatment intensification in high-risk breast cancer
Exploring the role of olaparib and treatment intensification in high-risk breast cancer
Expert on Demand: Dr Mark Shahin on Treating with Lynparza (olaparib)
Expert on Demand: Dr Mark Shahin on Treating with Lynparza (olaparib)